Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies find their products are best

Executive Summary

Industry-sponsored head-to-head statin trials are 20 times more likely to favor the sponsor's drug than a comparator, an article in the June issue of the Public Library of Science states. In an evaluation of 192 randomized controlled trials, Lisa Bero, University of California-San Francisco, et al., also finds that company-sponsored trials are 35 times more likely to reach a conclusion in favor of the sponsor's product. Antipsychotic trials have been found to be similarly biased (1"The Pink Sheet" Feb. 6, 2006, p. 9)...

You may also be interested in...



Antipsychotic Trials Biased Towards Sponsor’s Drug, Study Suggests

Clinical trial protocols for head-to-head comparisons of antipsychotic drugs should be reviewed by regulatory authorities like FDA to eliminate potential sources of bias, according to a recent analysis published in the American Journal of Psychiatry

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

PS048463

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel